Trial · NCT05784987
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05784987, Not applicable, Unknown, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. Trials, record NCT05784987. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05784987
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT number
- NCT05784987
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide, Etoposide, X: Orelabrutinib, X: Chidamide, X: Penpulimab, X: Lenalidomide
- First posted
- 2023-03-27
- Last updated
- 2023-03-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate(ORR) | up to 4 cycles of chemotherapy(each cycle is 21 days) | Objective response rate (ORR) after 4 cycles of R-MINE+X chemotherapy |
| Secondary | Complete remission rate(CRR) | up to 4 cycles of chemotherapy(each cycle is 21 days) | Complete remission rate(CRR) after 4 cycles of R-MINE+X chemotherapy |
| Secondary | Duration of remission(DOR) | up to 4 cycles of chemotherapy(each cycle is 21 days) | Time from reaching CR or PR for the first time to disease progression |
| Secondary | Progression-Free-Survival rate | 1 year | from date of inclusion to date of progression, relapse, or death from any cause |
| Secondary | Overall survival rate | 1 year | from the date of inclusion to date of death, irrespective of cause |
| Secondary | Adverse events (AE) | From the first day of medication to 28 days after the last dose | The safety of the drug was evaluated by NCI-CTC AE 5.0 standard |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42426809 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05784987
GET https://conductscience.org/api/trials/v1/NCT05784987/registered